These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 19808293)

  • 1. Phosphodiesterase type 5 inhibition: a support of the left ventricular assist device bridge to transplant.
    Semigran MJ
    Circ Heart Fail; 2008 Nov; 1(4):211-2. PubMed ID: 19808293
    [No Abstract]   [Full Text] [Related]  

  • 2. Phosphodiesterase inhibitors for pulmonary hypertension.
    Bergot E; Magnier R; Zalcman G
    N Engl J Med; 2010 Feb; 362(6):559; author reply 560. PubMed ID: 20147727
    [No Abstract]   [Full Text] [Related]  

  • 3. Phosphodiesterase inhibitors for pulmonary hypertension.
    Galiè N; Rubin LJ; Simonneau G
    N Engl J Med; 2010 Feb; 362(6):559-60; author reply 560. PubMed ID: 20175298
    [No Abstract]   [Full Text] [Related]  

  • 4. Preoperative administration of PDE-5 Inhibitors.
    Edwards AF; Roy RC
    J Clin Anesth; 2009 Mar; 21(2):149; author reply 149-50. PubMed ID: 19329023
    [No Abstract]   [Full Text] [Related]  

  • 5. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension.
    Archer SL; Michelakis ED
    N Engl J Med; 2009 Nov; 361(19):1864-71. PubMed ID: 19890129
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
    Botha P; Parry G; Dark JH; Macgowan GA
    J Heart Lung Transplant; 2009 Jul; 28(7):676-82. PubMed ID: 19560695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension.
    Schwartz BG; Kloner RA
    Circulation; 2010 Jul; 122(1):88-95. PubMed ID: 20606131
    [No Abstract]   [Full Text] [Related]  

  • 8. Phosphodiesterase type 5 inhibitors in pulmonary hypertension: a Hobson's choice for Indian patients.
    Saxena A
    Indian Heart J; 2007; 59(4):299-301. PubMed ID: 19126933
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiac anti-remodelling effects of phosphodiesterase type 5 inhibitors: afterload-(in)dependent?
    Kuhn M
    Cardiovasc Res; 2009 Apr; 82(1):4-6. PubMed ID: 19221131
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of sildenafil in acute posttransplant right ventricular dysfunction: successful experience in 13 consecutive patients.
    De Santo LS; Mastroianni C; Romano G; Amarelli C; Marra C; Maiello C; Galdieri N; Della Corte A; Cotrufo M; Caianiello G
    Transplant Proc; 2008; 40(6):2015-8. PubMed ID: 18675118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 5 phosphodiesterase inhibition in heart failure: the next step.
    Goldsmith SR
    J Am Coll Cardiol; 2007 Nov; 50(22):2145-7. PubMed ID: 18036452
    [No Abstract]   [Full Text] [Related]  

  • 12. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
    Schäfer S; Ellinghaus P; Janssen W; Kramer F; Lustig K; Milting H; Kast R; Klein M
    Cardiovasc Res; 2009 Apr; 82(1):30-9. PubMed ID: 19131365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of sildenafil in children with pulmonary arterial hypertension].
    He CY
    Zhongguo Dang Dai Er Ke Za Zhi; 2010 Jun; 12(6):509-12. PubMed ID: 20540870
    [No Abstract]   [Full Text] [Related]  

  • 14. Pulmonary hypertension and left heart disease: emerging concepts and treatment strategies.
    O'Callaghan DS; McNeil K
    Int J Clin Pract Suppl; 2008 Jul; (160):29-31. PubMed ID: 18638172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phosphodiesterase inhibitors in clinical practice. The present and the future. Part II].
    Baksheev BI; Kolomiets NM
    Klin Med (Mosk); 2007; 85(4):4-11. PubMed ID: 17564028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating heart failure with sildenafil.
    Blum A
    Congest Heart Fail; 2009; 15(4):181-5. PubMed ID: 19627292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation.
    Hemnes AR; Zaiman A; Champion HC
    Am J Physiol Lung Cell Mol Physiol; 2008 Jan; 294(1):L24-33. PubMed ID: 17965319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sildenafil in Eisenmenger syndrome: safety first.
    Wort SJ
    Int J Cardiol; 2007 Sep; 120(3):314-6. PubMed ID: 17477991
    [No Abstract]   [Full Text] [Related]  

  • 19. Levitra for sphincter of Oddi dysfunction? Are you kidding?
    Affronti J
    Gastrointest Endosc; 2009 May; 69(6):1117-9. PubMed ID: 19410043
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pulmonary hypertension in left heart disease].
    Opitz CF; Gläser S; Ewert R
    Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S167-9. PubMed ID: 19718607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.